INTS vs. BDTX, CADL, CRBU, GNFT, IPSC, MGX, ZURA, IPHA, ELEV, and IVVD
Should you be buying Intensity Therapeutics, Inc. Common stock stock or one of its competitors? The main competitors of Intensity Therapeutics, Inc. Common stock include Black Diamond Therapeutics (BDTX), Candel Therapeutics (CADL), Caribou Biosciences (CRBU), Genfit (GNFT), Century Therapeutics (IPSC), Metagenomi (MGX), Zura Bio (ZURA), Innate Pharma (IPHA), Elevation Oncology (ELEV), and Invivyd (IVVD). These companies are all part of the "biological products, except diagnostic" industry.
Black Diamond Therapeutics (NASDAQ:BDTX) and Intensity Therapeutics, Inc. Common stock (NASDAQ:INTS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, community ranking, media sentiment and dividends.
Black Diamond Therapeutics has a beta of 2.56, indicating that its stock price is 156% more volatile than the S&P 500. Comparatively, Intensity Therapeutics, Inc. Common stock has a beta of 4.03, indicating that its stock price is 303% more volatile than the S&P 500.
95.5% of Black Diamond Therapeutics shares are held by institutional investors. Comparatively, 3.7% of Intensity Therapeutics, Inc. Common stock shares are held by institutional investors. 8.9% of Black Diamond Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Black Diamond Therapeutics received 34 more outperform votes than Intensity Therapeutics, Inc. Common stock when rated by MarketBeat users. However, 100.00% of users gave Intensity Therapeutics, Inc. Common stock an outperform vote while only 63.93% of users gave Black Diamond Therapeutics an outperform vote.
Intensity Therapeutics, Inc. Common stock's return on equity of -72.94% beat Black Diamond Therapeutics' return on equity.
In the previous week, Black Diamond Therapeutics had 1 more articles in the media than Intensity Therapeutics, Inc. Common stock. MarketBeat recorded 3 mentions for Black Diamond Therapeutics and 2 mentions for Intensity Therapeutics, Inc. Common stock. Black Diamond Therapeutics' average media sentiment score of 1.89 beat Intensity Therapeutics, Inc. Common stock's score of 0.64 indicating that Intensity Therapeutics, Inc. Common stock is being referred to more favorably in the news media.
Black Diamond Therapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 151.05%. Intensity Therapeutics, Inc. Common stock has a consensus price target of $12.00, suggesting a potential upside of 141.45%. Given Intensity Therapeutics, Inc. Common stock's higher possible upside, research analysts clearly believe Black Diamond Therapeutics is more favorable than Intensity Therapeutics, Inc. Common stock.
Summary
Black Diamond Therapeutics beats Intensity Therapeutics, Inc. Common stock on 8 of the 12 factors compared between the two stocks.
Get Intensity Therapeutics, Inc. Common stock News Delivered to You Automatically
Sign up to receive the latest news and ratings for INTS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Intensity Therapeutics, Inc. Common stock Competitors List
Related Companies and Tools
